Continuity Image Blogs
Read article Continuity Without Compromise: How KCAS Bio Delivers End‑to‑End Bioanalytical Support Across Modalities

In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in Bioanalysis…

MethodDev-to-Testing_KCASBio Blogs
Read article PK Method Optimization and GLP In‑Study Sample Analysis in Rat and NHP Serum

Some molecules refuse to be easy to study. In this case, the drug was highly charged, sticky, and extremely sensitive to proteolysis, and previous partner labs had already struggled with it; “they’ve never seen anything like this before!” Keeping the entire process, from method transfer, optimization, validation, and GLP…

From LBA to LC-MS/MS: Solving the PK/PD Disconnect in Biotherapeutic Stability Blogs
Read article From LBA to LC-MS/MS: Solving the PK/PD Disconnect in Biotherapeutic Stability

Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In addition,…

SOT March 22 - March 25

KCAS Bio will be exhibiting at the Society of Toxicology (SOT) Annual Meeting and ToxExpo, taking place in San Diego, California on March 22-25, 2026. As one of the largest gatherings of toxicologists and life sciences professionals, this event offers a unique platform to connect with leaders in toxicology and…

Drug Discovery: an Essential Part of the Drug Development Process Blogs
Read article Inside the Drug Discovery Process: from Idea to Candidate

Drug discovery is an essential part of the drug development process. Researchers test candidates to identify those suitable for regulated animal studies and, ultimately, clinical trials. Bioanalytical discovery involves assessing a compound’s physiochemical properties,…

Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics webinars
Read article Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics

As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.

Pharmacokinetics vs Pharmacodynamics Blogs
Read article Pharmacokinetics vs Pharmacodynamics: Key Differences Explained

Understanding the intricate relationship between drugs and the human body is crucial for effective medical treatments. Two fundamental concepts in pharmacology – pharmacokinetics and pharmacodynamics – play pivotal roles in this understanding. This blog post will delve into these concepts, exploring their differences and significance in drug development and clinical…

What is a Generic PK Assay? Blogs
Read article Use of Generic PK Assays to Support Toxicology Studies for NBE

What is a generic PK assay? A generic pharmacokinetic (PK) assay, also referred to as a universal PK assay for New Biologic Entities (NBE), is used to measure circulating human biotherapeutics—primarily antibody-based—post-administration across various non-human matrices. These assays are particularly beneficial when drug-specific reagents, such as anti-idiotype antibodies, are…

KCAS-podcast-thumb_TWB-085 Podcasts
Listen to podcast Podcast (The Weekly Bioanalysis) Eps #85: “Patient-Centric Sampling: Beyond the Clinic and What it Means for Bioanalysis”

Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them found fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of…

KCAS-event-thumb_2024-011_SOT March 16 - March 20

KCAS Bio is excited to announce our participation in the Society of Toxicology (SOT) Annual Meeting and ToxExpo, taking place in Orlando, Florida on March 16th-20th. As one of the largest gatherings of toxicologists and life sciences professionals, this event offers a unique platform to connect with leaders in toxicology…

KCAS-podcast-thumb_TWB-084 Podcasts
Listen to podcast Podcast (The Weekly Bioanalysis) Eps #84: “Small Molecule LC-MS Development and Evolving Approaches to ADC Payloads”

In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…

KCAS-blog-thumb_2024-09_Pharmacokinetics Blogs
Read article The Importance of Pharmacokinetics in Drug Development

The Role of Pharmacokinetics (PK) in Drug R&D Pharmacokinetics (PK) is defined as the study of the fate of a new therapeutic entity (NTE) after it is administered into the body of animals or humans. It involves understanding how the drug is absorbed, distributed, metabolized, and eliminated (ADME). Essentially, PK…